Kinnate Biopharma Inc. (KNTE)
Market Cap | 258.93M |
Revenue (ttm) | n/a |
Net Income (ttm) | -116.27M |
Shares Out | 46.57M |
EPS (ttm) | -2.64 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 91,893 |
Open | 5.70 |
Previous Close | 5.76 |
Day's Range | 5.35 - 5.70 |
52-Week Range | 3.30 - 15.86 |
Beta | 0.19 |
Analysts | Buy |
Price Target | 29.29 (+426.8%) |
Earnings Date | May 11, 2023 |
About KNTE
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dep... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is $29.29, which is an increase of 426.80% from the latest price.
News

Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
SAN FRANCISCO and SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for ...

Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that a clinical trial ab...

Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China
SAN FRANCISCO and SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that it has acquired owne...

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
SAN FRANCISCO and SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and Dr...

Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
SAN FRANCISCO and SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive ...

Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directo...

Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation o...

Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the...

Can Kinnate Biopharma Inc. (KNTE) Climb 305% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Kinnate Biopharma Inc. (KNTE) points to a 305% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
SAN FRANCISCO and SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced an update from the ongoi...

Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: Here's What You Should Know
Kinnate Biopharma Inc. (KNTE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor
SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and D...

Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit
SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive...

Kinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare Conference
SAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive ...

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will par...

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
Preclinical data from a study of the Company's pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the meeting proceedings Preclinical data from a ...

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecul...

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting
Three poster presentations highlight the unmet need for targeted therapies in BRAF and/or NRAS-altered cancers, including non-small cell lung cancer and melanoma Three poster presentations highlight t...

Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting
Poster presentations to highlight data from ongoing studies of the company's lead Pan-RAF kinase inhibitor program, KIN-2787 Poster presentations to highlight data from ongoing studies of the company'...

Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies

Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting
Presentation to focus on antitumor activity of KIN-2787 in preclinical models of human BRAF-alteration driven non-small cell lung cancer Presentation to focus on antitumor activity of KIN-2787 in prec...

Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule...

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium
Presentation to highlight data from preclinical studies of the company's next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resist...

Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022 Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022